TELEDYNE TECHNOLOGIES INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TELEDYNE TECHNOLOGIES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Jan 3, 2016 | $1.02B | Mar 1, 2016 |
| FY2015 | Dec 28, 2014 | $1.07B | Mar 1, 2016 |
| FY2015 | Dec 29, 2013 | $1.03B | Mar 1, 2016 |
| FY2014 | Dec 30, 2012 | $831.70M | Feb 26, 2015 |
| FY2013 | Jan 1, 2012 | $689.90M | Feb 25, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $6.12B | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $5.67B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $5.64B | Feb 20, 2026 |
| FY2024 | Jan 1, 2023 | $5.46B | Feb 21, 2025 |
| FY2023 | Jan 2, 2022 | $4.61B | Feb 23, 2024 |
| FY2020 | Jan 3, 2021 | $809.30M | Feb 26, 2021 |
| FY2020 | Sep 27, 2020 | $749.00M | Feb 26, 2021 |
| FY2020 | Jun 28, 2020 | $743.30M | Feb 26, 2021 |
| FY2020 | Mar 29, 2020 | $784.60M | Feb 26, 2021 |
| FY2020 | Dec 29, 2019 | $834.20M | Feb 26, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $704.40M | Feb 27, 2018 |
| FY2017 | Oct 1, 2017 | $662.20M | Feb 27, 2018 |
| FY2017 | Jul 2, 2017 | $671.10M | Feb 27, 2018 |
| FY2017 | Apr 2, 2017 | $566.10M | Feb 27, 2018 |
| FY2017 | Jan 1, 2017 | $552.90M | Feb 27, 2018 |
| FY2017 | Oct 2, 2016 | $526.80M | Feb 27, 2018 |
| FY2017 | Jul 3, 2016 | $539.70M | Feb 27, 2018 |
| FY2017 | Apr 3, 2016 | $530.50M | Feb 27, 2018 |
| FY2016 | Jan 3, 2016 | $600.00M | Mar 2, 2017 |
| FY2016 | Sep 27, 2015 | $555.40M | Mar 2, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Jan 3, 2016 | $221.60M | Mar 1, 2016 |
| FY2015 | Sep 27, 2015 | $209.60M | Mar 1, 2016 |
| FY2015 | Jun 28, 2015 | $220.00M | Mar 1, 2016 |
| FY2015 | Mar 29, 2015 | $219.10M | Mar 1, 2016 |
| FY2015 | Dec 28, 2014 | $230.70M | Mar 1, 2016 |
| FY2015 | Sep 28, 2014 | $225.70M | Mar 1, 2016 |
| FY2015 | Jun 29, 2014 | $228.70M | Mar 1, 2016 |
| FY2015 | Mar 30, 2014 | $221.80M | Mar 1, 2016 |
| FY2014 | Dec 29, 2013 | $214.60M | Feb 26, 2015 |
| FY2014 | Sep 29, 2013 | $202.60M | Feb 26, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $894.80M | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $819.20M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $885.70M | Feb 20, 2026 |
| FY2024 | Jan 1, 2023 | $788.60M | Feb 21, 2025 |
| FY2023 | Jan 2, 2022 | $445.30M | Feb 23, 2024 |
| FY2020 | Jan 3, 2021 | $132.10M | Feb 26, 2021 |
| FY2020 | Sep 27, 2020 | $93.90M | Feb 26, 2021 |
| FY2020 | Jun 28, 2020 | $93.70M | Feb 26, 2021 |
| FY2020 | Mar 29, 2020 | $82.20M | Feb 26, 2021 |
| FY2020 | Dec 29, 2019 | $115.70M | Feb 26, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $1.15B | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $989.10M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $1.03B | Feb 20, 2026 |
| FY2024 | Jan 1, 2023 | $972.00M | Feb 21, 2025 |
| FY2023 | Jan 2, 2022 | $624.30M | Feb 23, 2024 |
| FY2020 | Jan 3, 2021 | $143.80M | Feb 26, 2021 |
| FY2020 | Sep 27, 2020 | $122.50M | Feb 26, 2021 |
| FY2020 | Jun 28, 2020 | $109.80M | Feb 26, 2021 |
| FY2020 | Mar 29, 2020 | $104.00M | Feb 26, 2021 |
| FY2020 | Dec 29, 2019 | $133.80M | Feb 26, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $317.30M | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $292.60M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $356.30M | Feb 20, 2026 |
| FY2024 | Jan 1, 2023 | $352.20M | Feb 21, 2025 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $931.10M | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $902.60M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $852.00M | Feb 20, 2026 |
| FY2024 | Jan 1, 2023 | $804.00M | Feb 21, 2025 |
| FY2023 | Jan 2, 2022 | $1.07B | Feb 23, 2024 |
| FY2020 | Jan 3, 2021 | $171.90M | Feb 26, 2021 |
| FY2020 | Sep 27, 2020 | $168.00M | Feb 26, 2021 |
| FY2020 | Jun 28, 2020 | $172.90M | Feb 26, 2021 |
| FY2020 | Mar 29, 2020 | $188.00M | Feb 26, 2021 |
| FY2020 | Dec 29, 2019 | $195.30M | Feb 26, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $1.19B | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $1.19B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $836.10M | Feb 20, 2026 |
| FY2024 | Jan 1, 2023 | $486.80M | Feb 21, 2025 |
| FY2023 | Jan 2, 2022 | $824.60M | Feb 23, 2024 |
| FY2022 | Jan 3, 2021 | $618.90M | Feb 24, 2023 |
| FY2021 | Dec 29, 2019 | $482.10M | Feb 25, 2022 |
| FY2020 | Dec 30, 2018 | $446.90M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $374.70M | Feb 24, 2020 |
| FY2018 | Jan 1, 2017 | $317.00M | Feb 25, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $117.30M | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $83.70M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $114.90M | Feb 20, 2026 |
| FY2024 | Jan 1, 2023 | $92.60M | Feb 21, 2025 |
| FY2023 | Jan 2, 2022 | $101.60M | Feb 23, 2024 |
| FY2022 | Jan 3, 2021 | $71.40M | Feb 24, 2023 |
| FY2021 | Dec 29, 2019 | $88.40M | Feb 25, 2022 |
| FY2020 | Dec 30, 2018 | $86.80M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $58.50M | Feb 24, 2020 |
| FY2018 | Jan 1, 2017 | $87.60M | Feb 25, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $15.29B | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $14.20B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $14.53B | Feb 20, 2026 |
| FY2024 | Jan 1, 2023 | $14.35B | Feb 21, 2025 |
| FY2023 | Jan 2, 2022 | $14.43B | Feb 23, 2024 |
| FY2022 | Jan 3, 2021 | $5.08B | Feb 24, 2023 |
| FY2021 | Dec 29, 2019 | $4.58B | Feb 25, 2022 |
| FY2019 | Dec 30, 2018 | $3.81B | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $3.85B | Feb 25, 2019 |
| FY2017 | Jan 1, 2017 | $2.77B | Feb 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $4.77B | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $4.65B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $5.30B | Feb 21, 2025 |
| FY2023 | Jan 1, 2023 | $6.18B | Feb 23, 2024 |
| FY2022 | Jan 2, 2022 | $6.81B | Feb 24, 2023 |
| FY2021 | Jan 3, 2021 | $1.86B | Feb 25, 2022 |
| FY2020 | Dec 29, 2019 | $1.87B | Feb 26, 2021 |
| FY2019 | Dec 30, 2018 | $1.58B | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $1.90B | Feb 25, 2019 |
| FY2017 | Jan 1, 2017 | $1.22B | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $10.51B | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $9.55B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $9.22B | Feb 20, 2026 |
| FY2025 | Jan 1, 2023 | $8.17B | Feb 20, 2026 |
| FY2024 | Jan 2, 2022 | $7.62B | Feb 21, 2025 |
| FY2023 | Jan 3, 2021 | $3.23B | Feb 23, 2024 |
| FY2022 | Dec 29, 2019 | $2.71B | Feb 24, 2023 |
| FY2021 | Dec 30, 2018 | $2.23B | Feb 25, 2022 |
| FY2020 | Dec 31, 2017 | $1.95B | Feb 26, 2021 |
| FY2019 | Jan 1, 2017 | $1.55B | Feb 24, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $8.69B | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $7.99B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $8.00B | Feb 20, 2026 |
| FY2024 | Jan 1, 2023 | $7.87B | Feb 21, 2025 |
| FY2023 | Jan 2, 2022 | $7.99B | Feb 23, 2024 |
| FY2022 | Jan 3, 2021 | $2.15B | Feb 24, 2023 |
| FY2021 | Dec 29, 2019 | $2.05B | Feb 25, 2022 |
| FY2020 | Dec 30, 2018 | $1.74B | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $1.78B | Feb 24, 2020 |
| FY2018 | Jan 1, 2017 | $1.19B | Feb 25, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $7.14B | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $6.27B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $5.45B | Feb 21, 2025 |
| FY2023 | Jan 1, 2023 | $4.56B | Feb 23, 2024 |
| FY2022 | Jan 2, 2022 | $3.77B | Feb 24, 2023 |
| FY2021 | Jan 3, 2021 | $3.33B | Feb 25, 2022 |
| FY2020 | Dec 29, 2019 | $2.93B | Feb 26, 2021 |
| FY2019 | Dec 30, 2018 | $2.52B | Feb 24, 2020 |
| FY2018 | Jan 1, 2018 | $2.14B | Feb 25, 2019 |
| FY2018 | Dec 31, 2017 | $2.14B | Feb 25, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $352.40M | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $649.80M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $648.30M | Feb 21, 2025 |
| FY2023 | Jan 1, 2023 | $638.10M | Feb 23, 2024 |
| FY2022 | Jan 2, 2022 | $474.70M | Feb 24, 2023 |
| FY2021 | Jan 3, 2021 | $673.10M | Feb 25, 2022 |
| FY2020 | Dec 29, 2019 | $199.50M | Feb 26, 2021 |
| FY2019 | Dec 30, 2018 | $142.50M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $70.90M | Feb 25, 2019 |
| FY2018 | Jan 1, 2017 | $98.60M | Feb 25, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $2.48B | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | $2.65B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $3.24B | Feb 21, 2025 |
| FY2023 | Jan 1, 2023 | $3.92B | Feb 23, 2024 |
| FY2022 | Jan 2, 2022 | $4.10B | Feb 24, 2023 |
| FY2021 | Jan 3, 2021 | $778.50M | Feb 25, 2022 |
| FY2020 | Dec 29, 2019 | $850.60M | Feb 26, 2021 |
| FY2019 | Dec 30, 2018 | $747.50M | Feb 24, 2020 |
| FY2016 | Jan 1, 2017 | $509.70M | Mar 2, 2017 |
| FY2016 | Jan 3, 2016 | $754.10M | Mar 2, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | 19 | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | 17 | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | 18 | Feb 20, 2026 |
| FY2024 | Jan 1, 2023 | 16 | Feb 21, 2025 |
| FY2023 | Jan 2, 2022 | 10 | Feb 23, 2024 |
| FY2020 | Jan 3, 2021 | 3 | Feb 26, 2021 |
| FY2020 | Sep 27, 2020 | 2 | Feb 26, 2021 |
| FY2020 | Jun 28, 2020 | 2 | Feb 26, 2021 |
| FY2020 | Mar 29, 2020 | 2 | Feb 26, 2021 |
| FY2020 | Dec 29, 2019 | 3 | Feb 26, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | 18 | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | 17 | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | 18 | Feb 20, 2026 |
| FY2024 | Jan 1, 2023 | 16 | Feb 21, 2025 |
| FY2023 | Jan 2, 2022 | 10 | Feb 23, 2024 |
| FY2020 | Jan 3, 2021 | 3 | Feb 26, 2021 |
| FY2020 | Sep 27, 2020 | 2 | Feb 26, 2021 |
| FY2020 | Jun 28, 2020 | 2 | Feb 26, 2021 |
| FY2020 | Mar 29, 2020 | 2 | Feb 26, 2021 |
| FY2020 | Dec 29, 2019 | 3 | Feb 26, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | 46.19M | Feb 20, 2026 |
| FY2025 | Dec 29, 2024 | 46.71M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | 47.33M | Feb 21, 2025 |
| FY2023 | Jan 1, 2023 | 46.91M | Feb 23, 2024 |
| FY2022 | Jan 2, 2022 | 46.69M | Feb 24, 2023 |
| FY2021 | Jan 3, 2021 | 36.95M | Feb 25, 2022 |
| FY2020 | Dec 29, 2019 | 36.55M | Feb 26, 2021 |
| FY2019 | Dec 30, 2018 | 36.09M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | 35.54M | Feb 25, 2019 |
| FY2017 | Jan 1, 2017 | 35.11M | Feb 27, 2018 |